Abstract

At the time of writing, posts tagged with #ozempic had been viewed almost 250 million times on the video hosting platform TikTok. A typical entry features a woman in her twenties or thirties outlining her experience in using injectable semaglutide, a GLP-1 receptor agonist, for weight loss (Ozempic is the branded product, manufactured by Novo Nordisk). A separate injectable semaglutide (Wegovy) at a different dose to Ozempic, has been approved for weight management by regulatory authorities in many countries, but with stipulations as to a BMI in the obesity or overweight range and weight-related co-morbidities.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call